148
Views
10
CrossRef citations to date
0
Altmetric
Review

Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis

Pages 583-591 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sofie Mauger, Ronald Fraser & Kathryn Gill. (2014) Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatric Disease and Treatment 10, pages 587-598.
Read now
Christopher M Doran, Marian Shanahan, Erol Digiusto, Susannah O’Brien & Richard P Mattick. (2006) Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD. Expert Review of Pharmacoeconomics & Outcomes Research 6:4, pages 437-446.
Read now

Articles from other publishers (8)

Shane Darke, Johan Duflou, Briony Larance, Michael Farrell & Julia Lappin. (2021) Characteristics and circumstances of death related to buprenorphine toxicity in Australia. Drug and Alcohol Dependence 218, pages 108360.
Crossref
Van Phuong Hoang, Marian Shanahan, Nagesh Shukla, Pascal Perez, Michael Farrell & Alison Ritter. (2016) A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Services Research 16:1.
Crossref
Louisa Degenhardt, Emily Stockings, John Strang, John Marsden & Wayne D. Hall. 2016. Disease Control Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders. Disease Control Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders 109 125 .
Carol Levin & Dan Chisholm. 2016. Disease Control Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders. Disease Control Priorities, Third Edition (Volume 4): Mental, Neurological, and Substance Use Disorders 219 236 .
Bach Xuan Tran & Long Thanh Nguyen. (2013) Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS. International Journal of Drug Policy 24:6, pages e105-e110.
Crossref
Jose Martinez-Raga, Francisco Gonzalez-Saiz, Julian Oñate, Itziar Oyagüez, Eliazar Sabater & Miguel A Casado. (2012) Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain. Health Economics Review 2:1.
Crossref
Jennifer S. Orman & Gillian M. Keating. (2009) Buprenorphine/Naloxone. Drugs 69:5, pages 577-607.
Crossref
M. P. Carrieri, L. Amass, G. M. Lucas, D. Vlahov, A. Wodak & G. E. Woody. (2006) Buprenorphine Use: The International Experience. Clinical Infectious Diseases 43:Supplement 4, pages S197-S215.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.